A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).

Authors

Benjamin Philip Levy

Mount Sinai Health Systems, New York, NY

Benjamin Philip Levy , Giuseppe Giaccone , Benjamin Besse , Damir Begic , Xiaoling Wu , Abderrahim Fandi , Luis Paz-Ares

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.

First Author: Tony S. K. Mok

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.

First Author: James Lorens

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.

First Author: Giuseppe Lo Russo